NCT02717572 is a Phase 1 clinical trial of Fludeoxyglucose F 18 in Solid Tumor, Adult, sponsored by Washington University School of Medicine.

Who is sponsoring NCT02717572?

NCT02717572 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT02717572?

Interventions in NCT02717572: Fludeoxyglucose F 18, Positron Emission Tomography, Computerized Tomography, Magnetic Resonance Imaging.

What condition does NCT02717572 study?

NCT02717572 studies Solid Tumor, Adult.

Is NCT02717572 still recruiting?

NCT02717572 is currently completed. Last updated 5 April 2019.

Last reviewed 2019-04-05 · How we verify

NCT02717572

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

Completed Phase 1 Last updated 5 April 2019

What this trial tests

Phase 1 trial testing Fludeoxyglucose F 18 in Solid Tumor, Adult in 19 participants. Completed in 5 June 2017.

Timeline

1 March 2016

Primary endpoint
5 June 2017

5 June 2017

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	19
Start date	1 March 2016
Primary completion	5 June 2017
Estimated completion	5 June 2017
Sites	1 location across United States

Drugs / interventions tested

Fludeoxyglucose F 18 — full drug profile →
Positron Emission Tomography
Computerized Tomography — full drug profile →
Magnetic Resonance Imaging

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the current study, the investigators plan to expand the knowledge of Positron Emission Tomography/Magnetic Resonance (PET/MR) reliability by assessing the repeatability of fludeoxyglucose (FDG) standardized uptake values (SUV) measurements, as well as apparent diffusion coefficients (ADC) measurements, in a broad population of patients with malignant solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Measurement Repeatability of 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Solid Tumors of the Pelvis.
Fraum TJ, Fowler KJ, Crandall JP, Laforest RA, et al · · 2019 · cited 20× · PMID 30733325 · DOI 10.2967/jnumed.118.218735
Repeatability of 18F-FDG PET Radiomic Features in Cervical Cancer.
Crandall JP, Fraum TJ, Lee M, Jiang L, et al · · 2021 · cited 16× · PMID 33008931 · DOI 10.2967/jnumed.120.247999

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02717572 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 5 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02717572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing